OBI announces the termination of OBI-3424-001 trial while continuing the collaboration of OBI-3424 with partners

1.Date of occurrence of the event:2024/03/11 2.Company name: OBI Pharma, Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios: NA 5.Cause of occurrence: Following a strategic portfolio review, the Company’s Board of Directors has decided to terminate the OBI-3424-001 trial, and to allocate resources to other priority projects. (1)OBI-3424 […]